SCHEMBL30775181

SCHEMBL30775181

Cc1cnccc1-c1nccc2c1CNC2

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNC P24863 2/20 0.36
CDK8 P49336 2/20 0.36
PDE10A Q9Y233 3/20 0.33
CHRNB2 P17787 1/20 0.33
CHRNA4 P43681 1/20 0.33
PDE2A O00408 2/20 0.33
PDE4A P27815 1/20 0.33
PDE4B Q07343 1/20 0.33
PDE4C Q08493 1/20 0.33
PDE4D Q08499 1/20 0.33
PIK3C3 Q8NEB9 1/20 0.33
CYP17A1 P05093 2/20 0.33
CYP1A2 P05177 2/20 0.33
ROCK2 O75116 1/20 0.32
GRM4 Q14833 1/20 0.31
CYP2A6 P11509 1/20 0.31
MAPK13 O15264 1/20 0.31
GCGR P47871 1/20 0.31
MAPK12 P53778 1/20 0.31
MAPK11 Q15759 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3411218 0.73 CYP2A6 (0.32) CYP1A2CYP2A6MAPK14
SCHEMBL30775353 0.72 CYP11B2 (0.37) PDE10ACYP2A6
Hydrochloric Acid SCHEMBL28970128 0.71 AURKB (0.47) CDK8
SCHEMBL30775299 0.70 MAPK1 (0.42) CCNCCDK8MAPK13GCGRMAPK12
SCHEMBL19358199 0.68 HTR2B (0.39)
SCHEMBL30775176 0.67 PARP10 (0.40) PDE10ACHRNB2CHRNA4ROCK2GRM4
SCHEMBL3423341 0.67 CCNC (0.50) CCNCCDK8PDE10APDE2ACYP1A2
SCHEMBL29378632 0.65
SCHEMBL1118591 0.65
SCHEMBL19431572 0.65 ATR (0.40) CCNCCDK8PDE10APDE2APDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US claimed
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof DONG-A ST CO., LTD. (KR) 2025-03-04 US disclosed
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof EIF2AK4, GCN1, GCGR CCNC 3820/4885CDK8 1456/4885PDE10A 789/4885
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF EIF2AK4, GCN1, GCGR CCNC 3820/4885CDK8 1456/4885PDE10A 789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.